Ecopetrol
EC
Apple
AAPL
D.R. Horton
DHI
4
Meritage Homes
MTH
5
Lennar Corp
LEN
US Stock MarketDetailed Quotes
ENSC Ensysce Biosciences
- 2.5600
- -0.6900-21.23%
Close Mar 31 16:00 ET
- 2.7000
- +0.1400+5.47%
Post 19:48 ET
3.60MMarket Cap-0.43P/E (TTM)
3.1350High2.5394Low61.44KVolume2.9100Open3.2500Pre Close173.45KTurnover6.85%Turnover RatioLossP/E (Static)1.41MShares14.670052wk High0.97P/B2.29MFloat Cap2.118052wk Low--Dividend TTM896.48KShs Float86364.0000Historical High--Div YieldTTM18.33%Amplitude2.1150Historical Low2.8220Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Ensysce Biosciences Stock Forum
Revolutionary Opioid Safety Technology Takes Center Stage at PAINWeek 2025
Ensysce Biosciences Narrows Losses to $8M, Secures FDA Breakthrough Status
How Ensysce's FDA Fast-Tracked Opioids Could Transform Pain Management Safety
Revolutionary Pain Management: This New Opioid Actually Prevents Overdose
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
Wednesday, 5th February at 8:00 am
~ Positive Enrollment Progress and Safety Data ~
~ FDA Attention Establishes Momentum in the Pain Treatment Space ~
SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company develo...
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
Wednesday, 22nd January at 8:00 am
~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~
SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential ...
No comment yet